Fujirebio Europe Receives Translational Research Funding From Alzheimer’s Drug Discovery Foundation for Development of a Fully Automated Plasma pTau181 Testing Solution
28.10.2021 12:10:00 EEST | Business Wire | Press release
H.U. Group Holdings Inc., and its wholly-owned subsidiary Fujirebio, today announced an agreement with the Diagnostics Accelerator initiative of the Alzheimer's Drug Discovery Foundation (ADDF) to accelerate the development of a plasma pTau181 detection assay on the fully automated LUMIPULSE® G immunoassay platform. pTau is recognized as an important fluid biomarker linked to the diagnosis of Alzheimer’s disease (AD). The ADDF Diagnostics Accelerator initiative is part of a collaboration with Gates Ventures and other philanthropic partners.
Blood-based testing could have the potential to become a simple, accessible, and scalable approach to help support the diagnosis of AD. Of all the AD blood biomarkers under investigation, pTau has particular promise1. Access to a fully automated Lumipulse® G plasma pTau181 assay will allow clinicians and clinical research professionals to measure plasma pTau181 levels with a high degree of precision and efficiency. The test could also help simplify AD drug clinical trial recruitment of eligible cohorts.
“We are pleased to begin this cooperation with the ADDF, cementing the active engagement of Fujirebio to reach new milestones in AD testing,” said Christiaan De Wilde, CEO of Fujirebio Europe. “Fujirebio has an unrivalled heritage as a pioneer in the field of AD research, and the desire to tackle this and other neurodegenerative diseases runs deep throughout our teams. The possibility of easily accessible blood tests for the fully automated diagnosis of AD is a breakthrough the world is eagerly waiting for.”
Fujirebio was the first company to develop and market cerebrospinal fluid (CSF) biomarkers under the Innogenetics brand over 25 years ago. Today these products are an essential part of routine AD testing in many parts of the world. Fujirebio remains the only company with such a comprehensive line-up of fully automated AD assays and consistently partners with organizations and clinical experts across the world to develop new pathways for earlier, easier and more complete neurodegenerative diagnostic tools. More information can be found at www.fujirebio.com/alzheimer.
About Fujirebio
Fujirebio is a global leader in the field of in vitro diagnostics (IVD) testing with more than 50 years’ experience in the conception, development, production and worldwide commercialization of robust IVD products. These span the range from specialized testing to fully automated routine clinical laboratory testing solutions covering a variety of disease states.
About the Diagnostics Accelerator
The Alzheimer’s Drug Discovery Foundation’s (ADDF) Diagnostics Accelerator is a collaborative research initiative funded by leading philanthropists including ADDF Co-Founder Leonard A. Lauder, Bill Gates, Jeff Bezos, MacKenzie Scott, the Dolby family, the Charles and Helen Schwab Foundation, and The Association for Frontotemporal Degeneration among others to fast-track the development of affordable and accessible diagnostic tools and biomarkers for Alzheimer's disease and related dementias.
References
1. Zetterberg & Blennow, Mol Neurodegener 2021; 16 :10.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211028005491/en/
Contact information
For media:
Christiaan De Wilde
CEO Fujirebio Europe
+32-9329-1703
Public Relations Section, Public Relations/Sustainability Dept.
+81-3-6279-0884
pr@hugp.com
For investors and analysts:
IR/SR Dept.
+81-3-5909-3337
ir@hugp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ABB Robotics and PSYONIC Use Human-Generated Data to Advance Robotic Dexterity16.6.2026 07:01:00 EEST | Press release
ABB Robotics is collaborating with California bionics company, PSYONIC, to advance robotic gripping and dexterity using a new approach that utilizes real-world manipulation data from human prosthetic use. By combining the PSYONIC Ability Hand with an ABB GoFa™ cobot, the collaboration will explore how touch and motion data generated by human prosthetic use can be used to train robots to perform delicate, variable tasks that have traditionally been difficult to automate. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612749544/en/ “Human dexterity and the instinctive understanding of how to handle different objects is one of the most difficult things to replicate in industrial-grade robotics, but it’s a fundamental need for truly autonomous and versatile robots,” said Marc Segura, President, ABB Robotics. “As we develop the next generation physical AI, robots will learn and understand the world as we do. This collaboration
Signaloid Announces Availability of Amazon AWS Machine Image (AMI) for Accelerating Compute Workloads Ranging from Finance to Reinforcement Learning16.6.2026 07:00:00 EEST | Press release
British computing technology company Signaloid today announced the release of the Signaloid Compute Engine Amazon Machine Image (AMI) via AWS Marketplace. The release enables organizations to deploy Signaloid’s distribution-extended compute hardware (UxHw®) technology within their Amazon Virtual Private Clouds (VPCs). The AMI provides access to UxHw, which delivers orders-of-magnitude performance improvements on x86_64 and ARM (AArch64) AWS Elastic Compute Cloud (EC2) instances. Without requiring software rewrites, UxHw enables existing applications to compute directly on probability distributions, automating algorithms such as Monte Carlo methods in finance and physics, importance sampling in reinforcement learning, and particle filters in physical AI and robotics. The technology works through binary translation and optimization at the LLVM intermediate representation (LLVM IR) level, with optional hardware acceleration via FPGAs and Signaloid’s C0-ASIC that was recently taped-out in
Murata Collaborates with Synopsys to Provide Simulation Models Through Ansys Electromagnetic and Thermal Analysis Tools16.6.2026 05:00:00 EEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) announces a new collaboration with Synopsys, Inc., enabling users of Synopsys' simulation tools to navigate directly to Murata's website to access and download the latest high-performance simulation models from Murata. The collaboration covers Synopsys' 3D electromagnetic field analysis tool Ansys HFSS™ and thermal analysis tool Ansys Icepak®, and marks a significant step toward streamlining the simulation workflow for electronic circuit designers. Murata is also the first company to offer passive component simulation models via Ansys Icepak*. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615241645/en/ [Murata Manufacturing Co., Ltd.] New collaboration with Synopsys As demand for high-speed, high-capacity communications continues to grow, electronic circuit design has become increasingly complex. Engineers must now account for a range of physical phenomena
Trimontium Launches with $1.5 billion in AUM, Redefining Flexible Capital Solutions16.6.2026 02:01:00 EEST | Press release
Trimontium (the “Firm”), an institutionally backed alternative asset manager specialising in flexible capital solutions, today announced its launch with $1.5 billion in assets under management. The Firm’s investment approach is rooted in credit and special-situations expertise, with the flexibility to originate and execute tailored financing solutions across the full capital structure for a wide range of corporate needs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615892895/en/ Trimontium Founder and CIO, Vlado Spasov Founded by former Blackstone executive Vlado Spasov, Trimontium is one of the largest first-time alternative asset managers based in Europe focused on flexible capital solutions to launch, according to available market data. The Firm is backed by leading institutional partners in the United States, Canada, Asia, and Australia, who collectively manage over $15 trillion in assets. Trimontium has sourced all
Newmont Announces Key Executive Appointments for the Next Phase of Delivery16.6.2026 00:20:00 EEST | Press release
Newmont Corporation (NYSE: NEM, ASX: NEM, PNGX: NEM) (“Newmont”) today announced leadership appointments that further shape its go-forward Executive Leadership Team under President and Chief Executive Officer Natascha Viljoen and reflect the depth of leadership talent within the company. Effective July 1, 2026, Brian Tabolt has been appointed Chief Financial Officer, Mark Rodgers has been appointed Chief Operating Officer, and David Thornton has been appointed Chief Technical Officer. In addition, David Fry has been promoted to Executive Vice President, Project Development, reflecting the importance of disciplined project development and execution as Newmont advances its highest-return growth opportunities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615487768/en/ Mark Rodgers - COO “These appointments bring together respected leaders with deep industry experience and a strong understanding of our operational, financia
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom